These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33828522)

  • 1. The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP.
    Burt RK; Tappenden P; Balabanov R; Han X; Quigley K; Snowden JA; Sharrack B
    Front Neurol; 2021; 12():645263. PubMed ID: 33828522
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Is it CIDP?
    Burt RK; Burman J; Barker A; Sharrack B
    Handb Clin Neurol; 2024; 202():199-238. PubMed ID: 39111908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
    Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
    Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy.
    Burt RK; Balabanov R; Tavee J; Han X; Sufit R; Ajroud-Driss S; Jovanovic B; Quigley K; Arnautovic I; Helenowski I; Sharrack B
    J Neurol; 2020 Nov; 267(11):3378-3391. PubMed ID: 32594300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Hematopoietic Stem Cell Transplantation for CIDP.
    Qin Z; Huang Q; Zou J; Tang L; Hu Z; Tang X
    Int J Med Sci; 2020; 17(2):234-241. PubMed ID: 32038107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review.
    Jaime-Pérez JC; Meléndez-Flores JD; Ramos-Dávila EM; González-Treviño M; Gómez-Almaguer D
    Cytotherapy; 2022 Jul; 24(7):676-685. PubMed ID: 35193829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study.
    Layton JB; Ritchey ME; Huang Z; Chavan S; Ay H; Souayah N; Anderson-Smits C
    Neurol Ther; 2023 Aug; 12(4):1171-1186. PubMed ID: 37195408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
    Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
    Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.
    Ellrichmann G; Gold R; Ayzenberg I; Yoon MS; Schneider-Gold C
    Ther Adv Neurol Disord; 2017 Feb; 10(2):91-101. PubMed ID: 28382108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Feyen L; Schaub C; Zimmermann J; Nitsch L
    Neurol Int; 2023 Mar; 15(1):405-414. PubMed ID: 36976670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIDP prognosis in patients with IVIG treatment-related fluctuations.
    Cook M; Pasnoor M; Ajroud-Driss S; Brannagan TH; Dimachkie MM; Allen JA
    Muscle Nerve; 2023 Jan; 67(1):69-73. PubMed ID: 36330716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
    Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
    Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.
    Guptill JT; Runken MC; Eaddy M; Lunacsek O; Fuldeore RM
    Am Health Drug Benefits; 2019 May; 12(3):127-135. PubMed ID: 31346365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    Zheng Y; Hu J; Sun C; Zhao C; Lin J
    Eur J Neurol; 2023 Aug; 30(8):2570-2582. PubMed ID: 37170791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.